KRAS Inhibitors Show Promise But Long Road Ahead, Say Experts
Tough Times For Cell Therapy
Harvard Medical School’s Dr. Bruce Chabner, Bayer Pharma’s global head of research and Roivant Sciences founder, among others, share their views on the challenges and path ahead for KRAS inhibitors and other oncology modalities including CAR-T therapy.
You may also be interested in...
Global R&D Heads Talk Superbugs, PROTACs And More
A panel of R&D experts from Merck’s EMD Serono, Boehringer Ingelheim, Takeda and Hilleman Labs discuss technologies like PROTACs and multi-specific antibodies, a superbug that could cause more damage than COVID-19 and the need for harmonized regulation that recognizes risk is essential to discovery
Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: pharma’s Q2 prospects; Bayer’s plans for the US launch of its CKD drug; big tobacco takes further steps into healthcare; KRAS’s emergence in oncology amid ongoing challenges; and tips for European biotech fundraising.
Mirati Marks Another Milestone With Adagrasib
Mirati executives are still being pushed to defend the safety profile for the KRAS G12C inhibitor adagrasib, which has been seen as a potential disadvantage relative to Amgen’s Lumakras.